home :: clinical trials :: treatment trials :: clinical trial
CLINICAL TRIALS 

  CLINICAL TRIAL
 
Genitourinary Clinical Trial
Reference
Advanced TCC: CALGB 90601

Title
A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY COMPARING GEMCITABINE, CISPLATIN, AND BEVACIZUMAB TO GEMCITABINE, CISPLATIN, AND PLACEBO IN PATIENTS WITH ADVANCED TRANSITIONAL CELL CARCINOMA

Description

ELIGIBILITY
  • Histologically or cytologically documented metastatic or unresectable transitional cell (urothelial) carcinoma of the urinary tract with progressive metastatic or locally advanced disease (T4B, N2, N3, or M1) and must not be candidates for potentially curative surgery or radiotherapy.

  • No history of peritoneal carcinomatosis

  • No known brain metastases
    TREATMENT
    Arm A
  • Patients receive Gemcitabine, Cisplatin, and Placebo

  • Arm B
  • Patients receive Gemcitabine, Cisplatin, and Bevacizumab


  • After completion of study therapy, patients are followed up periodically for up to 7 years.

    Additional Info
    On the web: http://www.clinicaltrials.gov/ct2/search

back to Genitourinary Clinical Trials 



©2004 MSCCOP & Mount Sinai Medical Center